Memorial Healthcare issued the following announcement on July 8
In June, Memorial Healthcare became the first Michigan hospital to treat patients suffering from migraines with Vyepti, the only migraine IV treatment. This medication reduces the rate of migraine by as much as 50% within 24 hours. Also, it exhibits little to no side effects.
“Vyepti can provide solace to patients who have struggled with migraine relief in the past,” said Dr. Amit Masih, Memorial Healthcare neurologist specializing in headache medicine. “At Memorial Healthcare, we continue to strive for the best treatments available, putting our patients at the front of care. When we were made aware of this new treatment option, we were determined to get approval for treatment as soon as possible.”
While 1 in 12 people suffer from migraines, no cure has been found. Vyepti is the most effective prevention treatment on the market, working in as little as 24 hours, while other treatments can take up to a week to show results.
This treatment is suitable for both episodic and chronic migraines. Memorial Healthcare is actively treating patients at its Owosso infusion center and is accepting patients in need of migraine relief.
The introduction of Vyepti is yet another example of Memorial Healthcare’s commitment to world-class, cutting-edge care for its patients – particularly within its neurological practice area. In the past year, Memorial Healthcare launched the first clinic-based research study of Multiple Sclerosis using Neurofilament Light Chain technology in the United States. In addition, Memorial Healthcare has begun construction of a $40 million facility specializing in neurology and orthopedics.
Memorial Healthcare has a strong track record of patient safety, including recently becoming the only mid-Michigan hospital to receive both an ‘A’ rating from The Leapfrog Group and four stars from the Centers for Medicare and Medicaid Services.
To schedule an appointment or for more information on the neurology department, visit the Memorial Healthcare Institute for Neuroscience website by clicking here.
Original source can be found here.
Alerts Sign-up